Skip to content

CervoMed Inc.: 10-Q filed 2026-08-07

What CervoMed Inc. reported in its quarterly report filed 2026-08-07 (fiscal Q2 2026): 28 published measures, 82 facts as tagged in accession 0001437749-26-026592.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-07
Fiscal period
fiscal Q2 2026
Accession
0001437749-26-026592 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CervoMed Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-3025,992,471USD
At 2025-12-3122,879,018USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-303,032,174USD
At 2025-12-314,656,117USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-3022,960,297USD
At 2026-03-3110,615,715USD
At 2025-12-3118,222,901USD
At 2025-06-3033,439,779USD
At 2025-03-3134,634,487USD
At 2024-12-3139,202,328USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-3022,462,577USD
At 2025-12-318,235,469USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-6,571,656USD91
2026-01-01 to 2026-06-30-14,535,814USD181
2025-04-01 to 2025-06-30-6,258,404USD91
2025-01-01 to 2025-06-30-11,152,438USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-14,936,763USD181
2025-01-01 to 2025-06-30-10,409,054USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-301,757,724USD91
2025-01-01 to 2025-06-303,675,215USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-3018,926,963USD181
2025-01-01 to 2025-06-304,588,687USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-3010,236,908USD181
2025-01-01 to 2025-06-305,141,584USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-112,233,665USD
At 2025-12-31-97,697,851USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3010,244,516shares91
2026-01-01 to 2026-06-309,754,142shares181
2025-04-01 to 2025-06-308,950,521shares91
2025-01-01 to 2025-06-308,827,305shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.64USD/shares91
2026-01-01 to 2026-06-30-1.49USD/shares181
2025-04-01 to 2025-06-30-0.7USD/shares91
2025-01-01 to 2025-06-30-1.26USD/shares181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30711,471USD181
2025-01-01 to 2025-06-30858,182USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-6,678,551USD91
2026-01-01 to 2026-06-30-14,789,075USD181
2025-04-01 to 2025-06-30-6,616,275USD91
2025-01-01 to 2025-06-30-11,919,159USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-3025,992,471USD
At 2025-12-3122,879,018USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-30687,111USD
At 2025-12-311,454,118USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-306,678,551USD91
2026-01-01 to 2026-06-3014,789,075USD181
2025-04-01 to 2025-06-308,373,999USD91
2025-01-01 to 2025-06-3015,594,374USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-304,321,772USD91
2026-01-01 to 2026-06-309,457,191USD181
2025-04-01 to 2025-06-305,108,625USD91
2025-01-01 to 2025-06-309,946,423USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3013,526,233shares
At 2025-12-319,252,719shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-30135,180,330USD
At 2025-12-31115,905,684USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30106USD
At 2025-12-315,816USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-30733,718USD
At 2025-12-311,267,005USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-6,571,342USD91
2026-01-01 to 2026-06-30-14,541,524USD181
2025-04-01 to 2025-06-30-6,280,410USD91
2025-01-01 to 2025-06-30-11,209,418USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,356,779USD91
2026-01-01 to 2026-06-305,331,884USD181
2025-04-01 to 2025-06-303,265,374USD91
2025-01-01 to 2025-06-305,647,951USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,998USD91
2026-01-01 to 2026-06-30977USD181
2025-04-01 to 2025-06-30-10,256USD91
2025-01-01 to 2025-06-30-10,391USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30106,895USD91
2026-01-01 to 2026-06-30253,261USD181
2025-04-01 to 2025-06-30357,871USD91
2025-01-01 to 2025-06-30766,721USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-426,993USD181
2025-01-01 to 2025-06-30106,744USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-767,007USD181
2025-01-01 to 2025-06-30272,592USD181

Inspect the source

Entity
CervoMed Inc. / CIK 0001053691
Captured
2026-09-20T05:17:36.273Z
SEC response SHA-256
0a28d9e08b18175e4a16bd2486e9ebae9dc8a6e8a3f7e429c0f71f98175b0255

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001053691.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))